TxCell is a cell therapy company based on the therapeutic potential of a population of immune cells known as type 1 regulatory T cells, notably for treating severe inflammatory disease.

TxCell has developed a proprietary GMP process for the production of antigen-specific Tr1. TxCell has already validated its cell therapy protocol in a mouse model and is now conducting clinical trials in Crohn's disease.